Menu
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Bristol-Myers Squibb (NY:BMY)

55.90 UNCHANGED
Streaming Delayed Price Updated: 7:00 PM EST, Jan 8, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Bristol-Myers Squibb

< Previous 1 2 3 4 5 6 7 8 9
...
85 86 Next >
News headline image
Bristol Myers Squibb Data at ASH 2025 Showcase Potential of Hematology Pipeline and Build Momentum for Next Generation Portfolio
From Bristol Myers Squibb
Via Business Wire
News headline image
2 Undervalued, High-Quality Companies to Buy Now and Hold Forever ↗
If you are looking to own a stock for the long term, these out-of-favor drugmakers have proven they have what it takes to survive. 
Via The Motley Fool
Topics Intellectual Property
News headline image
2 Top Dividend Stocks to Buy and Hold ↗
Patience will be rewarded for those who stick with these two healthcare stocks. 
Via The Motley Fool
Topics Artificial Intelligence Intellectual Property
Big Pharma Layoff Wave Extends Into Next Year: UNH, Merck, BMS, Novartis File New WARN Notices ↗
Via Stocktwits
Topics Workforce
News headline image
Should You Buy Bristol Myers Stock for Its 5.4%-Yielding Dividend? ↗
The pharma stock yields more than 4x the S&P 500 average. 
Via The Motley Fool
Topics Intellectual Property Stocks
News headline image
Bristol-Myers (BMY) Earnings Call Transcript ↗
Bristol-Myers (BMY) Earnings Call Transcript 
Via The Motley Fool
Topics Earnings
News headline image
BRISTOL-MYERS SQUIBB CO (NYSE:BMY) Offers a Compelling Mix of High Yield and Financial Strength for Dividend Investors ↗
Bristol-Myers Squibb (BMY) offers a strong 5.4% dividend yield, backed by a history of reliable payments, robust profitability, and a sound financial position for income investors. 
Via Chartmill
News headline image
Bristol Myers Squibb to Participate in Citi’s 2025 Global Healthcare Conference
From Bristol Myers Squibb
Via Business Wire
News headline image
Bristol Myers Squibb Receives Approval from the European Commission to Expand Use of CAR T Cell Therapy Breyanzi for Relapsed or Refractory Mantle Cell Lymphoma
From Bristol Myers Squibb
Via Business Wire
News headline image
PacBio, Bristol-Myers Squibb, Oscar Health, Centene, and Molina Healthcare Shares Are Soaring, What You Need To Know
A number of stocks jumped in the afternoon session after a Politico report revealed that the White House plans to pitch a two-year extension of Obamacare subsidies. The proposal would extend subsidies... 
Via StockStory
Topics Economy
News headline image
Monday's session: gap up and gap down stock in the S&P500 index ↗
Curious about the S&P500 stocks that are gapping on Monday? Explore the gap up and gap down stocks in the S&P500 index during today's session. 
Via Chartmill
News headline image
Which S&P500 stocks are moving before the opening bell on Monday? ↗
Before the opening bell on Monday, let's take a glimpse of the US markets and explore the S&P500 top gainers and losers in today's pre-market session. 
Via Chartmill
News headline image
Bristol Myers Squibb to Host Hematology-Focused Investor Event
From Bristol Myers Squibb
Via Business Wire
News headline image
What's Driving the Market Sentiment Around Bristol-Myers Squibb Co? ↗
 
Via Benzinga
News headline image
Why GRAIL Stock Could Be Biotech’s Next Big Breakout ↗
Via MarketBeat
News headline image
Market Movers in Motion: Merck & Co. and Amer Sports Chart Volatile Courses
The financial markets are a constant theater of dynamic shifts, and in recent months, two distinct players – pharmaceutical giant Merck & Co. and global sporting goods powerhouse Amer Sports – have... 
Via MarketMinute
Topics Economy Initial Public Offering Intellectual Property
News headline image
Bristol Myers Squibb Announces Accepted Amounts and Pricing Terms of its Tender Offers
From Bristol Myers Squibb
Via Business Wire
News headline image
Spotting Winners: Bristol-Myers Squibb (NYSE:BMY) And Branded Pharmaceuticals Stocks In Q3
Wrapping up Q3 earnings, we look at the numbers and key takeaways for the branded pharmaceuticals stocks, including Bristol-Myers Squibb (NYSE:BMY) and its peers. 
Via StockStory
Topics Artificial Intelligence Intellectual Property
News headline image
Bristol Myers Squibb Announces Early Participation Results, Amendment and Early Settlement of Tender Offers
From Bristol Myers Squibb
Via Business Wire
News headline image
1 Cash-Producing Stock to Keep an Eye On and 2 We Find Risky
A company that generates cash isn’t automatically a winner. Some businesses stockpile cash but fail to reinvest wisely, limiting their ability to expand. 
Via StockStory
News headline image
These 2 Dividend ETFs Are a Retiree's Best Friend ↗
Exchange-traded funds provide investors with exposure to a basket of stocks. Some also pay dividends. 
Via The Motley Fool
Topics Artificial Intelligence Bonds ETFs
News headline image
Fear Of An AI Bubble? This Sector Is Quietly Surging While Tech Sinks ↗
While AI stocks slide, healthcare is soaring. XLV leads November gains, outperforming tech as investors rotate. 
Via Benzinga
Topics Artificial Intelligence
News headline image
Stay informed with the top movers within the S&P500 index on Friday. ↗
Stay updated with the movements of the S&P500 index one hour before the close of the markets on Friday. Discover which stocks are leading as top gainers and losers in today's session. 
Via Chartmill
News headline image
Discover which S&P500 stocks are making waves on Friday. ↗
Stay informed about the performance of the S&P500 index in the middle of the day on Friday. Uncover the top gainers and losers in today's session for valuable insights. 
Via Chartmill
News headline image
Tech Rebounds After Selloff, Bitcoin Craters To $97,000: What's Moving Markets Friday? ↗
Investors stepped back into beaten-down tech names Friday, with the Nasdaq 100 rising 0.6% by midday in New York, staging a modest rebound after Thursday's sharp selloff. 
Via Benzinga
News headline image
Bristol Myers Faces Another Trial Disappointment As Heart Drug Milvexian Fails To Show Efficacy ↗
Bristol Myers and Johnson & Johnson ended the Librexia ACS trial after an interim review showed low efficacy, while AF and stroke studies continue with data expected in 2026. 
Via Benzinga
News headline image
Friday's session: gap up and gap down stock in the S&P500 index ↗
Wondering which stocks are making significant price gaps? Explore the S&P500 index on Friday to find the gap up and gap down stocks in today's session. 
Via Chartmill
News headline image
Bristol Myers Slumps After Its Heart Condition Study Gets The Boot ↗
An independent data monitoring committee said the company's treatment for acute coronary syndrome was likely to fail in testing. 
Via Investor's Business Daily
News headline image
Discover the top S&P500 movers in Friday's pre-market session. ↗
As we await the opening of the US market on Friday, let's delve into the pre-market session and discover the S&P500 top gainers and losers shaping the early market sentiment. 
Via Chartmill
News headline image
BMY Stock Slumps 5% After It Scraps Heart Drug Study ↗
The decision follows an analysis by an independent data monitoring committee that the trial is unlikely to meet its key goal. 
Via Stocktwits
< Previous 1 2 3 4 5 6 7 8 9
...
85 86 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.